Karius is a life sciences startup that operates in the medical diagnostics market, specifically focusing on infectious diseases. The company's primary offering is the Karius Test, a liquid biopsy that can detect over 1,000 pathogens from a single blood sample. This test is non-invasive and quick, making it a valuable tool for clinicians treating vulnerable hospitalized patients. It helps avoid the need for multiple invasive, low-yield diagnostic tests that can delay treatment.

The Karius Test uses advanced genomics and artificial intelligence (AI) to detect microbial cell-free DNA (mcfDNA), which are tiny fragments of DNA from microbes that are circulating in the bloodstream. This technology allows the company to provide unique insights into the pathogens causing infections.

The company's business model revolves around selling these diagnostic tests to healthcare providers. By providing a faster, non-invasive alternative to traditional diagnostic methods, Karius has the potential to save lives and reduce healthcare costs.

The company's proprietary machine learning algorithms analyze complex genomic data in real time, and their reference genome databases are constantly updated as more data becomes available. This continuous learning and improvement is a key part of the company's strategy to stay at the forefront of infectious disease diagnostics.

In summary, Karius is a life sciences company that uses advanced genomics and AI to provide rapid, non-invasive diagnostic tests for infectious diseases, serving healthcare providers and their patients.

Keywords: Life Sciences, Medical Diagnostics, Infectious Diseases, Non-Invasive Testing, Genomics, Artificial Intelligence, Microbial Cell-Free DNA, Healthcare Providers, Machine Learning, Real-Time Analysis.